ArticleInternational journal of genomics2026
Single-Cell and Bulk Transcriptomic Integration Reveals an Adverse SPP1 Inflammatory TAM State and INHBA as a Candidate Biomarker in Non-Small Cell Lung Cancer Immunotherapy.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-Cell and Bulk Transcriptomic Integration Reveals an Adverse SPP1 Inflammatory TAM State and INHBA as a Candidate Biomarker in Non-Small Cell Lung Cancer Immunotherapy.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomarkers that capture the microenvironmental basis of response to neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC) remain limited. We integrated single-cell and bulk transcriptomic data to identify response-associated immune programs with patient-level relevance. Methods: Single-cell RNA-seq and clinical annotations from GSE207422 were used to construct an NSCLC tumor microenvironment atlas and refine myeloid and T cell states. UCell scoring, sample-level summaries, pseudobulk differential analysis, Monocle2 trajectory inference, and targeted macrophage-T cell interaction analysis were applied. A posttreatment SPP1 inflammatory TAM-derived NR-TAM signature was projected to pretreatment bulk RNA-seq from the same cohort. INHBA was evaluated in pretreatment bulk data, TCGA-LUAD/TCGA-LUSC, and lung cancer cell line assays. Results: SPP1 inflammatory TAM was enriched in nonmajor pathologic response (NMPR) samples and co-occurred with exhausted CD8 T cell abundance, malignant cell hypoxia, and EMT programs. The NR-TAM signature was partially recapitulated in pretreatment bulk RNA-seq, with higher scores in NMPR but substantial group overlap. Exploratory ROC analysis showed modest discrimination for NR-TAM score (AUC = 0.60), INHBA (AUC = 0.64), and the combined model (AUC = 0.64; LOOCV AUC = 0.37). INHBA was higher in NMPR cases, correlated with residual tumor burden and selected TAM-related genes, showed less favorable survival trends particularly in LUSC, and its knockdown reduced proliferation and migration in lung cancer cells. Conclusions: An SPP1 inflammatory TAM program is associated with unfavorable pathologic response in NSCLC neoadjuvant immunotherapy. INHBA is a prioritized exploratory candidate within this program. Because the evidence is associative and predictive performance is modest, these markers require prospective validation before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.